Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Honestly, I’ve debated this multiple times...my heart says go it alone and become the next big boy in the industry and my head says take the guarantee and major payout. It’ll be interesting to watch how NP navigates this
This company has too much technology and connections for it to be trading at these levels..
Don’t think so. If You’re investing based on Cramer mentions, you should stop investing.
The data will be what it is. If it’s effective for Covid, the planet should celebrate. If not, it is what is it. I’d rather know that than watch a therapy be pumped. Leronlimab will have it’s day Covid indication or not
I’d guess we see leronlimab data released this week and an uplist in 2 weeks. Govt knows they need help beyond the current (ineffective) therapy available. Want to restore confidence and a sense of normalcy? Open schools, sporting events, the economy?? Therapeutics are needed and needed know. Leronlimab is one of the last remaining options available
I vaguely remember one of my rotations at the NIH back in the day. I sat in on meetings with high level individuals discussing therapeutics and implications of such. Knowledge of clinical data prior to is 100%. There’s a ton of logistics that come into play that need to be discussed before approval.
I’m not saying that’s what is happening here. I’m just saying it’s necessary in a situation like this
Announcement this week? I do appreciate that the CEO doesn’t feel compelled to release a bunch of hype and is managing this more like a blue chip stock. This will be a very different company in 6-12 months
I’m not going to speculate on anything Trump knows or thinks. However, he was clearly EXTREMELY high on some particular therapeutic. There simply aren’t that many far enough along (or remaining) other than leronlimab
$20 EOY? So, we’re looking for either a 15-20x valuation or MASSIVE movement in the pps based on what exactly? If some major partnership means guaranteed revs, I still doubt $20 is a thing this year. Given what the company has battled through the past 18 months, if we are seeing $3.44 warrants cashed in EOY I’ll be lighting up a fat cigar.
So insider trading. Got it
Shorty...you are done!! I just listened to a recording of Rory and it said
Hahahahaha....
Fantastic post
I imagine NP will be clarifying this and providing guidance as to exactly how they plan to proceed. This is too valuable not to push forward
This is such a smart post. Not that we shouldn’t be laser focused on therapies to prevent deaths associated with Covid, but the morbidity rates could (and will IMO) cause long term devastating effects for millions due to the complexity of the immune response to this virus
I’d imagine a PDUFA and uplisting would occur simultaneously. Getting this stock in the hands of institutional investors should be a top priority. It’s days on the OTC are numbered
Are you still supporting this company? It’s unfortunate what’s happened here and the means by which people were brought in. Maybe it’s time to reconcile and regain trust....
Watched a couple of tech companies (still OTC so take it with a grain of salt) blow up because the market is perfect for the product. Verb is close to making that happen. Massive user base and unique tech/applications. MMs aren’t shaking shares from anyone down here. If investors haven’t sold already, they won’t now. I just keep accumulating warrants...it’s going to happen this year.
Fine. This is a long term hold for me.
That’s sounds stupid.
You shorted this from $2.05?
No you didn’t...
Appreciate the update on this. It’s an important development to track the adoption and application of the tech
I’m not sure how much institutional buying takes place at this current pps. It’s hard to tell until filings reported. This is still OTC level at this pps. Regardless...the volume means something and I welcome the continued support
Sorry Black-Ops
I know this is waaaaay under you 5 year plan here. Believe me, I’d much rather have your projections come to fruition. I haven’t had the investment success you have over the years so I’m still low-balling this until I see something that changes the trajectory. The first approval will do that
I’ll play.
Without a current FDA approved drug....but with an approval from Mexico fast approaching....,
I’ll go with $30 plus Pfizer preferred stock
Good volume and movement the past several weeks. This keeps looking stronger month to month
Good volume. Consolidation taking place. Hopefully another leg up soon and start drawing more eyes. Hope there’s a continued stream of PRs coming out
Interesting take on the prospect of the company...little disappointing to read their target price for entry.
Thank you...I appreciate your time and thoughtful response. I’m glad you take the time to post here and share your experience and expectations for this company.
Triple digit pps goals seem a bit bullish before a single FDA approved indication has happened. The hurdles are enormous. I am cautiously optimistic about the MOA and wide ranging therapeutic options. But, I’ll set my target pps at $75 and be stupid happy with anything beyond that. It’ll be an interesting ride for the next 3-5 years
The FDA has no sway over Mexico or any other country evaluating leronlimab. The fact that the Mexico trial is 25 patients tells me they are expediting this...and with good reason. The FDA has too many interests beyond the patient for me to worry much about what they do. If it’s approved in the US first, great! If not, and they delay for some perceived reason other than what’s in the best interest of the patient, shame on them. Looking at the current therapeutic agents being used, leronlimab has a low bar to provide improvements in care. IMO
I’ve never seen an offering priced above market but I guess it could happen. Is an offering price discounted to market now a bad thing??
Anyway, the market price has probably 30-45 more days to move before the offering is priced. Heck, if Live hits the right nerve this could move very quickly in a short period of time
It’s an interesting AR arms race at this point. I’m not smart enough to know if IPNFF will rise to the top but it’s clear they are developing partnerships with significant companies to move the tech mainstream. The technology isn’t going anywhere, so watching to see if this company ends up as an acquisition target or builds itself to the point where uplisting becomes an option will be fun to watch.
The growth into international tech markets will be a key indicator
Would there be any downside to a buyback at this point in the process? I’m not sure we really need to buffer to meet uplist criteria (especially if significant news comes out), but having this be a $10-15 per share versus a $4-5 may create significant buying in the immediate post-uplist period by institutional investors that will be buying million share chunks.
Just looking for some feedback on the utility of it...academic discussion I guess
This is one of the reasons the Mexico study is so important as well. Sharing study results of a therapy with no SEs, no drug-drug interactions, and efficacy vastly superior to anything currently available. It’s so impressive in fact that Mexico has approved for use......the media blitz would be massive and the FDA knows this.
I’m not saying approval or uplist will occur in 2 weeks, but that’s a long time in the world in which we live. Additional attacks, catalysts, and major media outlets will start calling for updates.
In terms of big pharma calling....I’m praying the terms of a buyout are rejected HARD. This company is poised to change therapeutic options for a number of disease states. The conversation should be what smaller companies are good acquisition targets to expand upon what cydy has to offer. Besides, I don’t trust the BO process or the consideration of retail investors holdings....there’s too much power/money at stake
I do think there will be an additional 1-2 more substantial attacks to shake shares prior to the FDA approval. This company will experience nearly unprecedented manipulation in the next week as interested parties try and reposition themselves. If you think you can time the dips, more power to you. I will have available cash ready to buy and hold in the short term. Everyone has a different strategy. But the battle for shares is about to get vicious
Peter Lynch -"Everyone has the brain power to make money in stocks. Not everyone has the stomach."
Thank you for clarifying.
I’m skeptical of any Covid vaccine coming out. It would literally be the very first vaccine for an RNA virus...there’s a reason it hasn’t been accomplished. The efficacy will likely be poor and regardless you still need therapeutics for treatment. Vaccines don’t keep people from contracting, the hope is it helps the immune system handle the infection without the overwhelming response that is ultimately what kills people. I’m skeptical of any talk about a coronavirus vaccine.
Regardless, leronlimab will be needed sooner than later
I don’t think a buyout will be possible....a merger could be a possibility but I hope it doesn’t happen. In the next 3-5 years with the potential indications in the hopper, I could see CYDY doing the buyouts to add to their product line. I think we are looking at one of the next giants in the big pharma industry.
Who cares what the shorts do. Once this uplists they have to cover...they are going to get burned in the short time this stays OTC
If AR is involved, this product will be ready for mass distribution on the word go
Yes. This is the real deal